Any patient who is eligible for HSCT at the time of study screening
Prior allogeneic HSCT
Prior allogeneic HSCT
History of prior allogeneic HSCT
Matched related HSCT
Mismatched related HSCT
Patients will be eligible to receive donor-derived multiTAA-specific T cells following any type of allogeneic HSCT as:\r\n* Adjuvant therapy for ALL (group A), or\r\n* Treatment for relapsed/residual ALL disease (group B)
Any patient regardless of sex or age with CD19+ B-ALL undergoing allogeneic HSCT (Group A) OR any patient regardless of sex or age with CD19+ B-CLL or NHL undergoing allogeneic HSCT (Group B)
High risk of relapse after HSCT, defined as the presence of minimal residual disease as measured by flow cytometry in the absence of evidence of morphologic disease on a bone marrow biopsy prior to HSCT
Patient must be ?1 year and <75 years of age at screening and undergoing allogeneic HSCT.
Patient has had a prior autologous or allogeneic HSCT.
Life expectancy of > 12 months (exclusive of the disease for which the auto HSCT is being performed)
Participants who have received allogeneic HSCT within 90 days prior to randomization
Patients with prior hematopoietic stem cell transplant (HSCT) are eligible, with the exception of the following:\r\n* Autologous HSCT within 60 days of study entry\r\n* Allogeneic HSCT within 90 days of study entry\r\n* Evidence of graft-versus-host-disease (GVHD)\r\n* Treatment with immunosuppressive medications within 14 days; however, weaning or stable doses of steroids (must be =< 20 mg/m^2/day of prednisone equivalents) and/or calcineurin inhibitors are permitted
At the time of allogeneic HSCT:
No sooner than 45 days but no later than 90 days after allogeneic HSCT.
Have a diagnosis of primary aHUS, persistent HSCT-associated TMA or TTP
Patients with any type of autologous or allogeneic HSCT with CMV infection will be included
Patients excluded from this protocol are those with high risk hematologic malignancies in remission (and no prior allogeneic HSCT), where allogeneic HSCT is indicated but an appropriately matched HSC source (sibling, unrelated adult or UCB) is available
Patients who have received a prior allogeneic HSCT and who have either rejected their grafts or who have become tolerant of their grafts with no active GVHD requiring immunosuppressive therapy
Has undergone prior allogeneic HSCT:
204 Prior allogeneic HSCT.
Has received allogeneic hematopoietic cell transplantation (HSCT) within 3 months of planned infusion of genetically modified T cells; HSCT >= 3 months from CAR-T cell infusion eligible.
Prior allogeneic HSCT
Prior allogeneic HSCT
Less than 100 days for subjects receiving autologous hematologic stem cell transplant (HSCT); or 6 months for subjects receiving allogenic HSCT or either transplant type, if otherwise not fully recovered from HSCT related toxicity.
If post allogeneic HSCT, patient must not have less than 50% donor chimerism in either peripheral blood or bone marrow
No previous allogeneic HSCT
History of allogeneic HSCT or prior autologous HSCT
The patient has received allogeneic hematopoietic stem cell transplantation (HSCT) ? 3 months or autologous HSCT ? 21 days prior to start of Investigational Product (IP).
Recipient of an allogeneic HSCT.
Patients less than 30 days post HSCT
Any patient regardless of sex or age with CD19+ B-acute lymphoblastic leukemia (ALL) undergoing allogeneic HSCT (Group A); OR any patient regardless of sex or age with CD19+ B-chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL) undergoing allogeneic HSCT (Group B)
Any bone marrow relapse after allogeneic hematopoietic stem cell transplant (HSCT); subjects must be at least 100 days from HSCT at the time of screening and off immunosuppressant medication for at least 1 month at the time of screening, and have no active graft-vs-host disease (GVHD), or
The disease indication for which the participant required HSCT must be in remission
Prior allogeneic HSCT
Patient has received an HSCT transplant for a solid tumor disease.
Patients must have received crenolanib on RELHEM2 prior to HSCT to continue on to maintenance
immediately previous cancer chemotherapy, radiotherapy, or immunotherapy; and eligibility for allogeneic HSCT at the time of enrollment.
No prior allogeneic HSCT; and
Patients with relapsed disease following a prior HSCT may be enrolled into this study as an alternative to a second HSCT or as a bridge-to-transplant regimen.
Patients must have a diagnosis of leukemia/lymphoma undergoing active treatment or following HSCT for any indication. Leukemia/lymphoma will be defined according to the National Cancer Institute Surveillance Epidemiology and End Results Collaborative Staging Manual including those conditions defined as borderline such as myelodysplastic syndromes. All forms of HSCT will be eligible, allogeneic as well as autologous.
Previous HSCT procedure (autologous or allogeneic) pregnancy
Subjects must be undergoing autologous or allogeneic hematopoietic cell transplant (HSCT) with the BEAM conditioning regimen prior to HSCT
HSCT procedure scheduled within two months of consent
HSCT DYADS: In addition to meeting the inclusion criteria for HSCT patients and HSCT CGs, both parties must provide mutual agreement to participate as a dyad
HSCT DYADS: Participants must not meet the exclusion criteria for HSCT patients and HSCT CGs
HSCT DYADS: Patients or CGs who are participating in this study as individuals
No previous allogeneic HSCT
Requires voriconazole to prevent or treat invasive fungal infection (IFI) post HSCT
Preceding allogeneic HSCT
Receipt of an HSCT due to an oncological disease
No prior HSCT
Patients with prior history of HSCT
Undergoing allogeneic HSCT from a related or unrelated donor
Patients: Receiving an allogeneic HSCT
Undergoing an autologous or reduced intensity conditioning (RIC) allogeneic HSCT
Patients included in the study will have a hematologic malignancy (any stage or grade) for which they are undergoing preparation for allogeneic HSCT; participants in the study will be restricted to those undergoing HSCT under reduced-intensity protocols 9924 and 9907
Patient must be scheduled to undergo allogeneic hematopoietic stem cell transplant (HSCT) (adults or pediatric patients) or autologous HSCT (pediatric patients only) and be at high risk or very high risk of developing veno-occlusive disease (VOD).
Allogeneic HSCT recipients who are 3-35 months post-transplant
Allogeneic HSCT recipients who are 3-23 months post-transplant
Patients whom have failed prior attempts at allogeneic HSCT
Prior myeloablative allogeneic or autologous HSCT
Prior allogeneic HSCT
Allogeneic HSCT within 90 days of leukapheresis
Have had a prior allogeneic HSCT
Received a previous allogeneic HSCT (previous autologous HSCT is acceptable)
First allogeneic HSCT
Other chronic disease unrelated to HSCT that may impact bone metabolism
